Cognition Therapeutics (CGTX) Other Operating Expenses (2024 - 2025)
Cognition Therapeutics (CGTX) reported Other Operating Expenses of -$14.0 million for Q4 2025, down 32.44% year-over-year from -$20.7 million in Q4 2024, and down 32.44% on a QoQ basis from -$10.6 million in Q4 2024.
Cognition Therapeutics (CGTX) has 2 years of Other Operating Expenses data on file, last reported at -$14.0 million in Q4 2025.
- Quarterly Other Operating Expenses fell 32.44% year-over-year to -$14.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$14.0 million (down 32.44% YoY) and the FY2025 annual result came in at -$48.7 million, up 10.49% from the prior year.
- Other Operating Expenses eased to -$14.0 million in Q4 2025 per CGTX's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$10.6 million in Q4 2024 and bottomed at -$14.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.00 Mn |
| Dec 31, 2024 | -10.57 Mn |